Clinical trial
An Open-label Phase I Dose Finding Trial With BI 891065 Alone and in Combination With BI 754091 to Characterise Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced and/or Metastatic Malignancies
NCT03166631 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Phase I Dose Finding Trial With BI 891065 Alone and in Combination With BI 754091 to Characterise Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced and/or Metastatic Malignancies
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- September 8, 2017
- Completion date
- October 28, 2020
- Enrollment
- 62 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.